


pathways, which eventually causes cell-cycle arrest in the G1, S and G2/M phases, activation of DNA repair, and apoptotic cell death. (Bartek, Jiri, et al., "CHK2 Kinase - A Busy Messenger." Nature Reviews Molecular Cell Biology. Vol. 2(12) (2001) 877-886). Cancer cells often lack one or more genome -integrity checkpoints, so inhibition of CHK2 could make tumor cells selectively more sensitive to anti-cancer therapies, such as γ -radiation or DNA-damaging drugs.

[0010] Normal cells would still activate other checkpoints and recover, while cancer cells deprived of checkpoints would be more likely to die. It has been demonstrated that a peptide-based inhibitor of CHK2 abrogated the G2 checkpoint and sensitized p53-defective cancer cells to DNA damaging agents. (Pommier, Yves, et al., "Targeting Chk2 Kinase: Molecular Interaction Maps and Therapeutic Rationale." Current Pharmaceutical Design. Vol. 11, No. 22 (2005) 2855-2872).

[0011] CHK1 and/or CHK2 inhibitors are known, see for example, International Publication WO 2009/089352, WO2009/089359 and WO2009/140320.


[0012] SUMMARY OF THE INVENTION

[0013] ~~An aspect of the invention relates to~~ In one aspect, there is provided 5-bromo-4-chloro-3-nitro-1H-pyrrolo[2,3-b]pyridine of Formula I:




and stereoisomers, tautomers and pharmaceutically acceptable salts thereof. 5-bromo-4-chloro-3-nitro-1H-pyrrolo[2,3-b]pyridine of Formula I can be useful as an intermediate compound in a process for preparing compounds which can be used as Chk1 inhibitors.

[0013a] In one aspect, there is provided a process for preparing 5-bromo-4-chloro-3-nitro-1H-pyrrolo[2,3-b]pyridine of Formula I:



I

comprising the step of subjecting 4-chloro-3-nitro-1H-pyrrolo[2,3-b]pyridine of Formula II to a bromination:



II

to yield 5-bromo-4-chloro-3-nitro-1H-pyrrolo[2,3-b]pyridine of Formula I.

[0014] Another aspect ~~example~~ of the ~~invention disclosure~~ relates to processes for preparing 5-bromo-4-chloro-3-nitro-1H-pyrrolo[2,3-b]pyridine of Formula I.

[0015] DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS

[0016] Reference will now be made in detail to certain embodiments of the invention, examples of which are illustrated in the accompanying structures and formulas. While the